234 related articles for article (PubMed ID: 35492874)
1. Inhibiting 3βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer.
Hou Z; Huang S; Mei Z; Chen L; Guo J; Gao Y; Zhuang Q; Zhang X; Tan Q; Yang T; Liu Y; Chi Y; Qi L; Jiang T; Shao X; Wu Y; Xu X; Qin J; Ren R; Tang H; Wu D; Li Z
Cell Rep Med; 2022 Mar; 3(3):100561. PubMed ID: 35492874
[TBL] [Abstract][Full Text] [Related]
2. Chronic hypoxia stabilizes 3βHSD1 via autophagy suppression.
Qin L; Berk M; Chung YM; Cui D; Zhu Z; Chakraborty AA; Sharifi N
Cell Rep; 2024 Jan; 43(1):113575. PubMed ID: 38181788
[TBL] [Abstract][Full Text] [Related]
3. Prospective role of 3βHSD1 in prostate cancer precision medicine.
Zhuang Q; Huang S; Li Z
Prostate; 2023 May; 83(7):619-627. PubMed ID: 36842160
[TBL] [Abstract][Full Text] [Related]
4. AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.
Hettel D; Zhang A; Alyamani M; Berk M; Sharifi N
Endocrinology; 2018 Aug; 159(8):2884-2890. PubMed ID: 29850791
[TBL] [Abstract][Full Text] [Related]
5. Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro.
Pham S; Deb S; Ming DS; Adomat H; Hosseini-Beheshti E; Zoubeidi A; Gleave M; Guns ES
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():436-44. PubMed ID: 25201454
[TBL] [Abstract][Full Text] [Related]
6. Canonical and Noncanonical Androgen Metabolism and Activity.
Storbeck KH; Mostaghel EA
Adv Exp Med Biol; 2019; 1210():239-277. PubMed ID: 31900912
[TBL] [Abstract][Full Text] [Related]
7. Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment.
Mei Z; Yang T; Liu Y; Gao Y; Hou Z; Zhuang Q; He D; Zhang X; Tan Q; Zhu X; Qin Y; Chen X; Xu C; Bian C; Wang X; Wang C; Wu D; Huang S; Li Z
Cell Rep Med; 2022 May; 3(5):100608. PubMed ID: 35584629
[TBL] [Abstract][Full Text] [Related]
8. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.
Culig Z; Hobisch A; Cronauer MV; Cato AC; Hittmair A; Radmayr C; Eberle J; Bartsch G; Klocker H
Mol Endocrinol; 1993 Dec; 7(12):1541-50. PubMed ID: 8145761
[TBL] [Abstract][Full Text] [Related]
9. Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer.
Mostaghel EA; Zhang A; Hernandez S; Marck BT; Zhang X; Tamae D; Biehl HE; Tretiakova M; Bartlett J; Burns J; Dumpit R; Ang L; Matsumoto AM; Penning TM; Balk SP; Morrissey C; Corey E; True LD; Nelson PS
Clin Cancer Res; 2019 Jan; 25(1):426-439. PubMed ID: 30181386
[TBL] [Abstract][Full Text] [Related]
10. Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.
Zang T; Taplin ME; Tamae D; Xie W; Mesaros C; Zhang Z; Bubley G; Montgomery B; Balk SP; Mostaghel EA; Blair IA; Penning TM
Endocr Relat Cancer; 2017 Aug; 24(8):393-404. PubMed ID: 28663228
[TBL] [Abstract][Full Text] [Related]
11. Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation.
Mostaghel EA
Int J Biol Sci; 2014; 10(6):602-13. PubMed ID: 24948873
[TBL] [Abstract][Full Text] [Related]
12. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis.
Kumagai J; Hofland J; Erkens-Schulze S; Dits NF; Steenbergen J; Jenster G; Homma Y; de Jong FH; van Weerden WM
Prostate; 2013 Nov; 73(15):1636-50. PubMed ID: 23996639
[TBL] [Abstract][Full Text] [Related]
14. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.
Qu F; Xie W; Nakabayashi M; Zhang H; Jeong SH; Wang X; Komura K; Sweeney CJ; Sartor O; Lee GM; Kantoff PW
Clin Cancer Res; 2017 Feb; 23(3):726-734. PubMed ID: 27489290
[TBL] [Abstract][Full Text] [Related]
15. Progesterone receptor in the prostate: A potential suppressor for benign prostatic hyperplasia and prostate cancer.
Chen R; Yu Y; Dong X
J Steroid Biochem Mol Biol; 2017 Feb; 166():91-96. PubMed ID: 27125450
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor.
Zhao XY; Malloy PJ; Krishnan AV; Swami S; Navone NM; Peehl DM; Feldman D
Nat Med; 2000 Jun; 6(6):703-6. PubMed ID: 10835690
[TBL] [Abstract][Full Text] [Related]
17. HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.
Hettel D; Sharifi N
Nat Rev Urol; 2018 Mar; 15(3):191-196. PubMed ID: 29231195
[TBL] [Abstract][Full Text] [Related]
18. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.
Mostaghel EA; Marck BT; Plymate SR; Vessella RL; Balk S; Matsumoto AM; Nelson PS; Montgomery RB
Clin Cancer Res; 2011 Sep; 17(18):5913-25. PubMed ID: 21807635
[TBL] [Abstract][Full Text] [Related]
19. Androgens in prostate cancer: A tale that never ends.
Hou Z; Huang S; Li Z
Cancer Lett; 2021 Sep; 516():1-12. PubMed ID: 34052327
[TBL] [Abstract][Full Text] [Related]
20. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.
Li R; Evaul K; Sharma KK; Chang KH; Yoshimoto J; Liu J; Auchus RJ; Sharifi N
Clin Cancer Res; 2012 Jul; 18(13):3571-9. PubMed ID: 22753664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
